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Introduction
　Intrahepatic cholangiocarcinoma (ICC) is a comparative-
ly rare cancer and one of the most difficult cancers to treat. 
Although surgical resection is the best therapeutic strategy 
for this malignant disorder, the long-term outcome after 
surgical intervention remains unfavorable because of fre-
quent local and/or regional lymph node recurrences [1, 2]. 
The 5-year survival rate for patients with curative resection 
is 20-40% [1-5]. Heterochronous metastasis to the adrenal 
glands from ICC is uncommon, and to the best of our knowl-
edge no resected cases have been reported. We report herein 






 　A 61-year-old Japanese man who had been followed-up 
for ICC after curative resection at our hospital was diag-
nosed with a nodule in the left adrenal gland. At the age of 
58 years, he had undergone right hepatic lobectomy with 
regional lymph node resection for nodular-type ICC in he-
patic segment 6. The histopathologic findings of the liver 
tumor had showed poorly differentiated adenocarcinoma 
without metastatic lymph node (T2N0M0 StageⅡ). The pa-
tientʼs post-operative course had been uneventful. The pa-
tient had received post-operative adjuvant chemotherapy 
with gemcitabine for 6 months. Three years after the initial 
surgery, abdominal computed tomography (CT) revealed a 
nodule in the left adrenal gland (Fig. 1). In addition, posi-
tron emission tomography/computed tomography (PET/CT) 
showed significant fluorodeoxyglucose (FDG) uptake at the 
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left adrenal gland [standardized uptake rate (SUV) MAX 
early phase＝5.6, late phase=8.1], with suspicion of a malig-
nant tumor (Fig. 2). Routine hematologic and biochemical 
examinations were normal. Serum levels of carcinoembry-
onic antigen and carbohydrate antigen 19-9 were within 
normal limits. Adrenal hormone, including vanillylman-
delic acid in the urine, 4 renin, aldosterone, and adrenocor-
ticotropic hormone, were all within normal limits. Serum 
and urine laboratory data showed that the mass was non-
functioning. Reevaluation 4 months later with contrast-en-
hanced CT demonstrated a progressively enlarging solitary 
nodule in the left adrenal gland. However, no swollen lymph 
nodes, local recurrences, or distant metastases were noted. 
Therefore, we diagnosed the nodule in the left adrenal gland 
as metastasis from ICC. Thirty months after the initial op-
eration, the patient underwent a laparosopic left adrenalec-
tomy operation by a laparoscopic left transperitoneal ap-
proach, in order to establish a definitive diagnosis. Surgery 
was performed with the patient in the flank position under 
CO2 pneumoperitoneum at 12 cmH2O. A 12 mm port was 
inserted at the umbilicus, and another 12 mm port was in-
serted at a location of about 3 cm to the left of, and above, 
the umbilicus. Two 5 mm ports were also inserted: one at 
the lateral border of the rectus abdominis mid and the other 
under the left costal margin. The distal pancreas and the 
spleen were mobilized and retracted by a snake retractor 
(Mediflex®) to expose the inferior left adrenal gland. The 
procedure required extensive adhesiolysis, but otherwise, 
dissection of the tumor proceeded without intraoperative 5 
complications. The left adrenal vein and artery were identi-
fied and divided by a LigaSure (Valleylab, Boulder, CO) 
device. The specimen was extracted through the umbilical 
trocar site. The patient was discharged uneventfully on the 
10th postoperative day without any complications. The cut 
surface of the surgical specimen showed a solid mass lesion 
measuring 3.0 cm×3.5 cm (Fig. 3A). Histologically, the le-
sion consisted of atypical epithelial cell proliferation with 
focal duct formation (Fig. 3B). The pathologic findings were 
similar to those of the primary lesion of cholangiocarcino-
ma (data not shown). 
　Immunohistochemically, the tumor cells were positive 
for cytokeratin 19 (CK19) and cytokeratin 7 (CK7) (Fig. 3C, 
D). CK19 and CK7 are normally expressed in the lining of 
the gastro-entero-pancreatic and hepato-biliary tracts. Thus, 
the tumor in the left adrenal gland appeared compatible 
with metastatic cholangiocarcinoma. The patient received 
postoperative chemotherapy with seven cycles of S-1. Ten 
months after the second operation, para-aortic lymph node 
metastasis recurred, along with left kidney metastases and 
multiple liver metastases. The patient received palliative 






　The adrenal gland is not a common site for metastases 
from ICC. Zheng et al. [6] reported that the majority of met-
astatic lesions in the adrenal gland occurred after early de-
tection of a primary tumor of which the lung was the most 
common primary tumor site, followed by kidney, liver, 
breast, melanoma, and others. The histological types of ad-
renal metastasis of patients who underwent adrenalectomy 
were estimated as follows: small cell lung carcinoma, non-
Figure 1. Three years after the initial surgery, CT revealed a nod-
ule, measuring 3.0 cm × 3.8 cm, in the left adrenal gland.
Figure 2. PET/CT showed significant FDG uptake at the left ad-
renal gland [SUV MAX early phase ＝ 5.6, late phase=8.1] and 
suspected malignant tumor.
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small cell lung carcinoma, kidney clear cell carcinoma, he-
patocellular carcinoma, melanoma, breast cancer, and un-
known carcinoma. The worldwide literature to date on 
adrenalectomy for metastasis from ICC is limited to case 
reports. To our knowledge, a few cases of synchronous ad-
renal metastasis from ICC have been described [7]. On the 
other hand, our case is the first report of adrenalectomy for 
heterochronous metastasis from ICC. Several reports have 
suggested that selected patients with isolated adrenal metas-
tasis from non-small cell lung carcinoma can achieve long-
term survival following adrenalectomy and definitive treat-
ment of the primary tumor [8-10]. For non-small cell lung 
carcinoma patients, it was also found that patients with syn-
chronous metastasis who underwent adrenalectomy had a 
shorter median overall survival than those with heterochro-
nous metastasis for an isolated adrenal metastasis [10]. Cho-
langiocarcinomas have often metastasized to distant organs, 
and 18F-FDG PET is valuable for discovering unsuspected 
distant metastases of cholangiocarcinoma [11-13]. There is 
no standardized SUV cutoff point for discriminating be-
tween benign disease and cholangiocarcinoma, but there 
are several studies about the usefulness of PET/CT for cho-
langiocarcinoma. Ruys et al. [14] reported that, for hilar 
cholangiocarcinoma, patients with distant metastases had 
significantly higher SUVs for the primary tumor. Reinhardt 
et al. [15] reported that 3.6 is the ideal SUV cutoff point for 
discriminating between benign disease and cholangiocarci-
noma. In our case, SUV MAX in the early phase was 5.6 
and that in the late phase was 8.1, so this SUV point sug-
gested that the left adrenal gland was a malignant tumor. 
Because surgical resection is the only curative treatment for 
ICC, 18F-FDG PET may be useful for the appropriate man-
agement of metastasis from ICC [16, 17]. 
　Surgical resection of the liver is the only curative treat-
ment for ICC patients; its 5-year survival rate is around 30
％, with a median overall survival of 2-3 years [1-5]. There 
is little support from evidence-based evaluation for the ef-
ficacy of chemotherapy for ICC patients. However, recent 
advances facilitate the use of chemotherapy to achieve a re-
sponse rate of around 30％ and a median survival of more 
than one year for ICC patients. Key drugs currently avail-
able for the therapy are gemcitabine, fluoropyrimidines, and 
Figure 3A.  The cut surface of the surgical specimen showed a solid mass lesion measuring 3.0 cm × 3.5 cm.
Figure 3B. Histologically, there were normal adrenocortical cells on the left upper side and atypical epithelial 
cell proliferation with focal duct formation (arrow) on the right lower side. The pathologic findings were simi-
lar to those of the primary lesion of cholangiocarcinoma (hematoxylin and eosin staining, 14 × 100.) Arrows 
indicate tumor cells. Figure 3C, D. Immunohistochemically, the tumor cells were positive for cytokeratin 19 
(CK19) (C) and cytokeratin7 (CK7) (D). Adrenocortical cells were negative for CK19 (C) and CK7 (D). (x100) 
Arrows indicate tumor cells.
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platinums [18, 19]. Treatment options for metastasis from 
ICC are limited, so surgical resection may be a clinical op-
tion for sporadic metastasis from ICC. Further investiga-
tions are required for the development of new agents, such 
as molecular-targeting drugs, and for combined therapy 
with surgery.
　To the best of our knowledge, this is the first case of het-
erochronous adrenal metastasis from ICC. Although un-
common, the adrenal grand should be considered among 
possible metastasis in patients who have a history of intra-
hepatic cholangiocarcinoma.
